DRUG-INDUCED OSTEONECROSIS OF THE JAWS
- 作者: Basin E.1, Medvedev Y.1, Polyakov K.1
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University
- 期: 卷 26, 编号 3 (2015)
- 页面: 66-68
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/116311
- ID: 116311
如何引用文章
详细
The paper gives an update on jaw osteonecrosis occurring with the use of different drugs.
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
E. Basin
I.M. Sechenov First Moscow State Medical University
Email: kroko-stomatolog@mail.ru
Candidate of Medical Sciences
Yu. Medvedev
I.M. Sechenov First Moscow State Medical University
Email: kroko-stomatolog@mail.ru
Professor
K. Polyakov
I.M. Sechenov First Moscow State Medical University
Email: kroko-stomatolog@mail.ru
Candidate of Medical Sciences
参考
- Майман Г.М. Клиника и патогенез хронической фосфорной интоксикации // Горьковский мед. журн. - 1934; 4-5: 81-105.
- Брунс Г.Ф. Фосфорное омертвение лицевых костей // Врач. - 1880; 1 (47): 772; 1 (49): 804-7; 1 (50): 829-35.
- Ruggiero S., Dodson T., Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw - 2014 Update // J. Oral Maxillofac. Surg. - 2014; doi: 10.1016/j. joms.2014.04.031.
- Hillner B., Ingle J., Chlebowski R. et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer // J. Clin. Oncol. - 2003; 21: 4042.
- Saad F., Gleason D., Murray R. et al.: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma // J. Natl. Cancer Inst. - 2002; 94: 1458.
- Saad F., Gleason D., Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer // J. Natl. Cancer Inst. - 2004; 96: 879.
- Rosen L., Gordon D., Tchekmedyian N. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial // Cancer. - 2004; 100: 2613.
- Rosen L., Gordon D., Kaminski M. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial // Cancer J. - 2001; 7: 377.
- Berenson J., Hillner B., Kyle R. et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma // J. Clin. Oncol. - 2002; 20: 3719.
- Physicians' Desk Reference. 57th ed. Montvale / NJ: Medical Economics, 2003.
- Letocha A., Cintas H., Troendle J. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement // J. Bone Miner. Res. - 2005; 20: 977.
- Watts N. Bisphosphonate treatment of osteoporosis // Clin. Geriatr. Med. -2003; 19: 395.
- Delmas P. The use of bisphosphonates in the treatment of osteoporosis // Curr. Opin. Rheumatol. - 2005; 17: 462.
- Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic // J. Oral Maxillofac. Surg. - 2003; 61: 1115-7.
- Ruggiero S., Mehrotra B., Rosenberg T. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases // J. Oral Maxillofac. Surg. - 2004; 62: 527-34.
- Bagan J., Murillo J., Jimenez Y. et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases // J. Oral Pathol. Med. -2005; 34: 120-3.
- Marx R., Sawatari Y., Fortin M. et al. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment // J. Oral Maxillofac. Surg. - 2005; 63: 1567-75.
- Durie B., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates // N. Engl. J. Med. - 2005; 353: 99-102.
- Bennett C., Nebeker J., Lyons E. et al. The Research on Adverse Drug Events and Reports (RADAR) project // JAMA. - 2005; 293: 2131-40.
- Qi W., Tang L., He A. et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials // Int. J. Clin. Oncol. - 2013; 19 (2): doi: 10.1007/s10147-013-0561-6.
- Scagliotti G., Hirsh V., Siena S. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study // J. Thorac. Oncol. - 2012; 7: 1823.
- Рузин Г.П., Ткаченко О.В. Клинико-рентгенологические варианты течения остеомиелита костей лица у наркозависимых больных // Український стоматологічний альманах. - 2013; 1: 46-50.
- Нестеров А.П., Нестеров А.А., Хабибов Я.Т. Патогенез одонтогенного остеомиелита челюстей у лиц с зависимостью от дезоморфина // Дентал Юг. - 2012; 102 (6): 42-4.
- Баранник Н.Г., Варжапетян С.Д., Мосейко А.А. и др. Опыт лечения пациентов с остеомиелитом челюстей и вторичным иммунодефицитом на фоне приема наркотических препаратов. Актуальні питання медичної науки та практики: Зб. наук. пр. ДЗ «ЗМАПО МОЗ України». Запоріжжя. 2013; 1 (1) Вып. 80: 12-20.
- Мостовой С.О., Остапенко О.В., Шульгин В.Ф. Идентификация этиологического фактора, вызывающего «винтовые остеомилиты», и оценка его воздействия на костную ткань и мочевиделительную систему лабораторных белых крыс // Ученые записки Таврического национального университета им. В.И. Вернадского Серия «Биология, химия». - 2012; 25 (64): 244-51.
- Marx R. Uncovering the cause of «phossy jaw» circa 1858 to 1906: Oral and maxillofacial surgery closed case file - Case closed // J. Oral. Maxillofac. Surg. -2008; 66: 2356.
补充文件
![](/img/style/loading.gif)